Small DNA tumour viruses, such as simian virus 40 (SV40), papilloma viruses and adenoviruses, encode proteins that form complexes with and inactivate the p53 and retinoblastoma (RB) proteins. This convergent evolution reflects the common need of these viruses to inactivate these two important regulators of cell cycle progression and cell survival. Polyomavirus, a close relative of SV40, is different. Its large T protein complexes only with RB, not with p53. We have examined whether this is compensated by the frequent appearance of p53 mutations in polyomavirus-induced tumours. We tested the p53 status of 15 polyomavirus-induced sarcomas. Two sarcomas were p53-negative while six carried mutant p53. Another six sarcomas expressed low levels of wild-type p53. One tumour expressed high levels of wild-type p53 protein as shown by DNA sequencing and immunofluorescence
Introduction
The p53 gene is often inactivated by point mutation or deletion in a wide variety of human and rodent tumours (Greenblatt et al., 1994) . Moreover, p53 null mice develop spontaneous tumours with a dramatically increased incidence (Donehower et al., 1992) , supporting the notion that p53 is a crucial tumour suppressor. p53 is expressed at low levels under normal conditions, but accumulates due to protein stabilization in response to DNA damage (Maltzman & Czyzyk, 1984 ; Kastan et al., 1991 ; Fritsche et al., 1993) or induction of cell proliferation by the E1A and c-myc oncogenes (Debbas & White, 1993 ; Hermeking & Eick, 1994 ; Lowe et al., 1994 ; Wagner et al., 1994) . The increased p53 levels cause cell cycle arrest in the G " phase or cell death through apoptosis (for a review see Selivanova & Wiman, 1995) .
The p53 protein is a sequence-specific transcription factor that transactivates genes, such as those encoding WAF1\p21, Author for correspondence : Klas G. Wiman.
Fax j46 8 33 04 98. e-mail Klas.Wiman!mtc.ki.se staining. MDM2 amplification was not detected in any of the tumours, but Northern blotting showed that MDM2 was overexpressed in at least two tumours that expressed wild-type p53 and in one tumour that expressed both wild-type and mutant p53. Treatment with the DNA-damaging agent mitomycin C caused p53 protein accumulation followed by induction of MDM2 and WAF1/p21 mRNA in four of the tumours expressing wild-type p53, indicating that p53-mediated transcriptional activation was unaltered in these tumours. However, p53-mediated transactivation of WAF1/p21 was impaired in the wild-type p53-expressing tumours that expressed elevated levels of MDM2. These results demonstrate that p53 mutation and inactivation are frequently but not invariably involved in polyomavirus-induced tumorigenesis.
MDM2, GADD45, cyclin G, Bax and Fas (reviewed by Ko & Prives, 1996) . Transactivation of WAF1\p21 is important for p53-induced cell cycle arrest but is dispensable for p53-induced apoptosis (Deng et al., 1995 ; Waldman et al., 1995) . However, transactivation of bax and fas may facilitate apoptosis (see Ko & Prives, 1996) . p53-mediated transactivation of MDM2 constitutes an autoregulatory feedback loop that modulates the activity of p53 (Wu et al., 1993) . The MDM2 protein can inhibit p53-mediated transcriptional activation by binding an N-terminal region of p53 that coincides with the acidic transactivation domain (Oliner et al., 1993) . Overexpression of MDM2 increases the tumorigenicity of NIH3T3 cells and overcomes wild-type p53-mediated suppression of cell growth (Fakharzadeh et al., 1991 ; Finlay, 1993) . Amplification and overexpression of this gene are frequently observed in human sarcomas (Oliner et al., 1992) .
More recent data have indicated that the early embryonic lethality of MDM2-deficient mice can be rescued by lack of p53, suggesting that MDM2 is a vital negative regulator of p53 activity during embryonic development (de Oca Luna et al., 1995 ; Jones et al., 1995) . p53 can also be inactivated at the protein level by complexing with virus oncoproteins, including simian virus 40 (SV40) large T (LT), adenovirus E1B 55 kDa protein (55K protein) and human papillomavirus (HPV)-16\18 E6 proteins (reviewed by Levine, 1990) . The fact that the virus protein domains that interact with p53 are essential for their transformation action indicates that inactivation of p53 is critical for the transformation capacity of these viruses. Virus oncoprotein-mediated inactivation of p53 may have evolved to ensure S phase entry and virus DNA replication following infection, of which transformation is merely a pathological consequence.
Polyoma is a DNA tumour virus that can induce a wide variety of tumours in newborn mice, hamsters, rats and rabbits (Grodzicker & Hopkins, 1981 ; Topp et al., 1981) . The early region of the polyomavirus genome encodes three T antigens, LT, middle T (MT) and small T (ST), with molecular masses of 100, 55 and 22 kDa, respectively. The polyomavirus LT antigen shares 60 % amino acid sequence identity and a wide range of biological and biochemical properties with the LT antigen encoded by the closely related SV40 (Soeda et al., 1980 ; Turler, 1980 ; Depamphilis & Bradley, 1986) . However, polyoma LT differs from SV40 LT in that it cannot cause malignant transformation by itself, although it can immortalize primary rat embryo fibroblasts (Asselin & Bastin, 1985 ; Cowie et al., 1986 ; Jat & Sharp, 1986) . Moreover, while both SV40 and polyoma LT form complexes with the retinoblastoma (RB) protein, SV40 LT but not polyoma LT binds p53 (DeCaprio et al., 1988 ; Wang et al., 1989 ; Dyson et al., 1990 ; Lin & Simmons, 1991) . The polyoma MT antigen can transform established cells in culture, but induction of tumours in rats or efficient transformation of primary rat embryo fibroblasts usually requires cooperation with either polyoma LT or ST (Treisman et al., 1981 ; Asselin et al., 1983 Asselin et al., , 1986 . There is no evidence indicating that MT forms a physical complex with p53.
If polyomavirus does not encode any function that blocks p53, and inactivation of the p53 pathway is a requirement for the development of polyomavirus-induced tumours, one would expect to find p53 mutations and\or deletions, MDM2 overexpression or other lesions that disrupt p53 function at high frequency in polyomavirus-induced sarcomas. Here, we have examined the status of the p53 and MDM2 genes as well as the transcriptional transactivation function of p53 in 15 polyomavirus-induced sarcomas and sarcoma cell lines. Our data demonstrate that p53 inactivation by point mutation, deletion or MDM2 overexpression occurs frequently in polyomavirus-induced sarcomas.
Methods
Tumours and cell culture. Three polyomavirus-induced sarcoma cell lines from C3H\Bi Da mice, A1633, A4412 and A4455, and two such lines from (BALB\cby JiC3H\Bi Da)F " mice, A4300 and A3377, were provided by Thomas Benjamin, Harvard Medical School, USA. The other polyomavirus-induced sarcomas (see Table 1 ) were established in our laboratory by inoculation of newborn mice (ABY, ACA, ASW, A\sn, CBA and C75BL strains) with polyomavirus. SEAC and SEWE are primary tumours. The other tumours have been passaged in adult mice between 5 and 47 times. Cells were grown at 37 mC in 5% CO # in Iscove's medium supplemented with 10 % heat-inactivated foetal calf serum, 1000 units\ml penicillin, 100 µg\ml streptomycin and 2 mM -glutamine. For mitomycin C (MMC) treatment, the cells were fed with the same medium containing 5 µg\ml MMC (Sigma) and harvested 0, 5 or 18 h later.
Metabolic labelling and immunoprecipitation. Radiolabelling with [$&S]methionine and immunoprecipitation were performed as described by Wiman et al. (1991) . The antibodies used were PAb246, specific for wild-type p53, PAb240, specific for mutant p53, and PAb421, recognizing both wild-type and mutant p53. All anti-p53 antibodies were from Oncogene Science.
Immunofluorescence staining. Monolayer cells were grown on sterile coverslips. Cells growing in suspension were spun on slides with a Cytospin cytocentrifuge at 900 r.p.m. for 10 min. Cells were fixed in methanol-acetone (1 : 1) at k20 mC for 10 min, rehydrated with balanced salt solution (BSS) for 60 min, and incubated in blocking solution (2 % bovine serum albumin, 5 % glycerol, 0n2 % Tween 20 and 0n02 % azide in PBS) for 30 min. The anti-p53 antibody PAb421 or the anti-polyomavirus LT antibody 711 (provided by Stephen Dilworth, Royal Postgraduate Medical School, London, UK) was then incubated for 60 min at a 1 : 50 dilution in this blocking solution. After washing three times with BSS, the cells were incubated for 30 min with FITC-conjugated rabbit anti-mouse IgG (Dako) or with FITC-conjugated rabbit anti-rat IgG (Dako) diluted 1 : 20 in the blocking solution. For double layer fluorescent staining, FITCconjugated swine anti-rabbit IgG (Dako) was added at a dilution of 1 : 200 for an additional 30 min. All incubations were carried out at room temperature. The second antibody solution always contained 0n4 µg\mI Hoechst 33258 (Farbwerke Hoechst) for DNA staining and to monitor the absence of mycoplasma contamination. Finally, the cells were washed three times with BSS and mounted with BSS-glycerol (1 : 1) containing 2n5 % 1,4-diazabicyclo[2.2.2]octane (Sigma) anti-fading reagent.
PCR and DNA sequencing. Total RNA was extracted as described by Chomczynski & Sacchi (1987) . First-strand cDNA was synthesized from 1-2 µg total RNA using avian myeloblastosis virus reverse transcriptase (Seikagaku America). PCR amplification of cDNA was carried out using primers E4F (5h CACTGCATGGACGATCTGTT 3h) and E9RB (5h CGGATCTTGAGGGTGAAATA 3h), flanking exons 4-9 in p53 and producing an 875 bp fragment that contains amino acid codons 97-320. Primer E9RB was biotinylated at the 5h end. The biotinylated strand of the PCR product was isolated with streptavidincoated iron beads (Dynal) and sequenced using the two primers E4F2 (5h GCCCCTGTCATCTTTTGTCCC 3h) and E6F (5h CTCCTCCCCAGC-ATCTTATCC 3h), located in exons 4 and 6, respectively. DNA sequencing was performed using the Solid Phase sequencing method (Hultman et al., 1991) and using the Autoread kit together with fluorescein-labelled dATP on an ALF automated sequencer (Pharmacia) (Voss et al., 1992) .
Southern blotting. High molecular mass DNA was prepared as described by Sambrook et al. (1989) . Five µg DNA from each sample was digested overnight with 25 units EcoRI. After electrophoresis on 0n8% agarose gels in TAE buffer, the DNA was transferred to Hybond-N nylon filters (Amersham) and hybridized with a $#P-labelled mouse MDM2 cDNA probe. RNA preparation and Northern blot analysis. RNA was prepared from approximately 5i10' asynchronously growing cells as described by Dooley et al. (1989) , with the following modifications. To release the nuclei, the cells were lysed in buffer I (1 % NP40 ; 150 mM NaCl ; 100 mM Tris-HCl, pH 7n5 ; 5 mM EDTA) containing 1 mM of the RNase inhibitor aurintricarboxylic acid (ATA) (Sigma) (Williams & Krawisz, 1989) . The nuclei were removed by centrifugation and the supernatant was mixed with an equal volume of buffer II (7 M urea ; 1 % SDS ; 350 mM NaCl ; 10 mM EDTA ; 10 mM Tris-HCl, pH 7n5), followed by phenol-chloroform extraction and precipitation with 1n3 vol. 2-propanol. ATA at a final concentration of 0n1 mM was added to 20i SSC during transfer. Ten µg RNA from each sample was fractionated on formaldehyde-agarose gels, transferred to nylon filters, and subsequently hybridized overnight with a mouse MDM2 cDNA probe or a mouse WAF1\p21 cDNA probe at 42 mC in 50 % formamide, 6i SSC, 0n2% SDS, 5i Denhardt's solution, 200 µg herring sperm DNA and 0n1 mM ATA. The integrity of the RNA and loading differences were assessed by ethidium bromide staining and\or by hybridization with a human GAPDH cDNA probe.
Western blot analysis. Total cell extracts were prepared by direct lysis in Laemmli buffer without bromphenol blue. Protein concentration was determined using the Bio-Rad protein assay kit. Samples containing 50 µg protein were separated on 10 % SDS-PAGE gels and transferred to Hybond-C extra nitrocellulose membranes (Amersham). Blocking and incubation with antibodies were performed in 5 % milk in PBS. Immunodetection using the ECL system (Amersham) was performed according to the manufacturer's instructions. The antibodies used were the rat monoclonal antibody 711 against the polyomavirus LT antigen and the rat monoclonal antibody 815 against the polyomavirus MT antigen, provided by Thomas Benjamin, Harvard Medical School, USA.
Results p53 gene status and p53 protein levels
We examined p53 in 15 polyomavirus-induced sarcomas using immunoprecipitation with the antibodies PAb421 (recognizing both wild-type and mutant p53), PAb240 (specific for mutant p53) and PAb246 (specific for wild-type p53), immunofluorescence staining with PAb421, and DNA sequencing of exons 4-9. The results are summarized in Table  1 . Two tumours, SEBB and SECA, were completely p53-negative. Six tumours expressed low levels of wild-type p53. One tumour, SEYF, expressed elevated levels of wild-type p53. The remaining six tumours carried mutant p53. The mutantspecific PAb240 failed to precipitate p53 from SEAC and A4300, and PAb246 reacted with p53 in both tumours ; however, both SEAC and A4300 expressed high levels of p53 (Figs 1 and 2 ; data not shown). DNA sequencing revealed a mutation in codon 272 in SEAC, resulting in a Pro His substitution. No wild-type sequence was detected, indicating that only the mutant allele was present. DNA sequencing also revealed that A4300 carried one wild-type p53 allele and one mutant allele with a mutation in codon 142 that resulted in a Ser Arg substitution and a mutation in codon 147 that caused an Ala Asp substitution. A4412 carried a mutation in codon 145, resulting in a Pro Ser substitution. No wild-type sequence was detected. SEWA-ADH carried a splice donor site mutation, resulting in an Arg Ser substitution at codon 258, followed by the insertion of five extra amino acids, as previously described by Magnusson et al. (1995) . Immunoprecipitation with the PAb246 antibody indicated that wildtype p53 was also expressed in this tumour line. Another subline of SEWA, SEWA-NA, also carried mutant p53 but did not express wild-type p53 according to immunoprecipitation with PAb240 and PAb246 (Table 1) . Altogether 8 out of 15 polyomavirus-induced sarcomas and sarcoma cell lines (53 %) had p53 mutation or were p53-negative. p53 protein levels were also analysed by immunostaining (Fig. 2) . Tumours carrying only wild-type p53 expressed low or undetectable levels of p53, with the exception of SEYF, which expressed p53 protein levels that were readily detected by immunostaining. All tumours carrying mutant p53 expressed high levels of the protein.
MDM2 gene status and expression
In order to test whether p53 inactivation had occurred by other mechanisms in the tumours carrying only wild-type p53, we investigated the status of MDM2 in all our polyomavirusinduced tumours and cell lines. Southern blot analysis using a mouse MDM2 cDNA probe revealed the germ line 14n2 and 2n7 kb MDM2 EcoRI fragments in all 15 tumours. No tumour had MDM2 gene amplification, as demonstrated by the equal intensity of the MDM2 hybridizing bands in all tumours (data not shown). However, Northern blot analysis showed significantly elevated MDM2 mRNA levels in three of the sarcomas : SESO, which expressed low levels of wild-type p53 ; SEYF, which expressed high levels of wild-type p53 ; and A4300, which carried both wild-type and mutant p53. MDM2 levels were also elevated in SE7E ( Fig. 3 ; Table 1 ).
p53-mediated transcriptional transactivation
To assess whether the transcriptional transactivation function of p53 remained intact in the tumours that expressed wildtype p53, we treated these tumour cells with the DNAdamaging agent MMC and examined whether the p53 protein accumulated and whether two p53-responsive genes, MDM2 and WAF1\p21, were induced. Immunostaining revealed increased p53 protein levels after MMC treatment in all the tumours expressing only wild-type p53, except SEYF, which expressed high levels of p53 even before treatment ( Fig. 2 ; Table 2 ; and data not shown). Tumours carrying mutant p53 expressed high levels of p53 both prior to and following MMC treatment.
As shown in Fig. 4 and Table 2 , MDM2 was strongly induced after MMC treatment in the tumours that expressed low levels of wild-type p53. WAF1\p21 was also significantly induced in all these tumours except SESO (if the GAPDH signal is taken into account) and SE7E ( Fig. 4 ; Table 2 ). Thus, p53-mediated transcriptional transactivation of MDM2 and WAF1\p21 was apparently unaltered in four tumours that expressed low levels of wild-type p53, whereas two tumours in this group showed reduced p53-mediated transactivation of 
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WAF1\p21. SEYF, which expressed high levels of MDM2 and WAF1\p21 prior to MMC treatment, showed only a minor induction of both genes. In contrast, all tumours carrying mutant p53, except A4300, expressed low or undetectable levels of WAF1\p21 and MDM2, and in most cases showed little or no induction of these genes after MMC treatment ( Fig.  4 ; Table 2 ). A4300 expressed relatively high levels of WAF1\p21 and MDM2 both prior to and following treatment. WAF1\p21 was markedly induced in SEAC, but the absolute levels were very low (Fig. 4) . SEBB and SECA, the two p53-negative sarcomas, showed a minor induction of both MDM2 and WAF1\p21 after MMC treatment. Since WAF1\p21 is probably the main downstream effector of p53-induced cell cycle arrest, it is conceivable that this gene might be inactivated by some mechanism in the polyomavirusinduced tumours that express wild-type p53. However, both Southern blot analysis (not shown) and the Northern blot analysis shown in Fig. 4 demonstrated that WAF1\p21 was not deleted in any of the tumours. Furthermore, the Northern blot analysis revealed normal size WAF1\p21 transcripts in all tumours studied.
Expression of polyomavirus LT and MT antigens
Although neither polyomavirus LT nor MT can bind p53 (Villareal & Fan, 1989 ; Wang et al., 1989) , it remains possible that they interfere with p53 function downstream of p53 in the p53 pathway or in a more indirect way. If this is the case, their expression in polyomavirus-induced tumours may show a correlation with p53 status. We therefore examined the expression of polyomavirus LT and MT in our series of sarcomas. As shown in Fig. 5 (a) and summarized in Table 3 , five out of the seven sarcomas carrying wild-type p53 expressed polyomavirus LT and\or its truncated forms, with a high level of expression in four tumours. Four out of the eight tumours that either carried mutant p53 or were completely negative for p53 expressed LT, with a high level of expression in two tumours. Only a small fraction of the A1633, SEAC and A4412 cells were positive in LT immunofluorescence staining, and Western blot analysis revealed barely detectable LT levels in these tumours (Fig. 5 a ; and data not shown). The tumours that expressed LT protein also expressed LT mRNA according to Northern blot analysis (data not shown). In contrast, the MT antigen was expressed at variable levels in all of the tumours (Fig. 5 b ; Table 3 ). Thus, neither LT nor MT expression showed a strict correlation with p53 status, although LT expression was more frequent and higher in the tumours carrying only wild-type p53 than in those carrying mutant p53. 
Discussion
The p53 and RB proteins play critical roles in the regulation of cell proliferation and survival. RB is probably an important component of the restriction point, R, in the G " phase of the cell cycle (reviewed by Weinberg, 1995) . p53 can induce expression of the cyclin-cdk inhibitor WAF1\p21, which inhibits cyclin D-CDK4\6-mediated phosphorylation of RB, and thus prevents inactivation of the gate-keeping function of RB in G "
. In addition, p53 can induce cell death by apoptosis. The adenovirus E1A protein that binds and inactivates RB induces p53 protein accumulation followed by apoptosis (Debbas & White, 1993 ; Lowe et al., 1994) . The p53-triggered apoptosis in response to E1A is inhibited by the adenovirus E1B 19 kDa (19K) and 55K proteins (Debbas & White, 1993) . This reflects the general need of DNA tumour viruses to both stimulate progression of the infected cell into S phase by blocking RB, and to prevent apoptosis triggered by the accumulation of p53 in response to induction of cell cycle progression.
Like the LT antigen encoded by the closely related SV40 virus, and the E1A and E7 proteins encoded by oncogenic subtypes of adenovirus and HPV, respectively, the polyomavirus LT antigen targets and inactivates the RB protein. This is an essential requirement for the ability of the virus to induce host DNA synthesis and timely synthesis of virus DNA, and to immortalize primary rat embryo fibroblasts (Dyson et al., 1990 ; Larose et al., 1991 ; Freund et al., 1992 Freund et al., , 1994 . However, unlike the other three viruses, polyomavirus does not encode any protein that complexes with p53 and directly blocks its function. Polyomavirus LT does not bind p53 (Wang et al., 1989) , and there are no published data indicating that polyomavirus MT and ST might bind p53. This raises the possibility that polyomavirus has evolved other mechanisms to escape wild-type p53-induced cell cycle arrest and apoptosis. Despite their similar genomic structure, polyomavirus, but not SV40, encodes the MT antigen, a transforming protein known to bind several cellular proteins, including pp60-c-Src, pp62-cYes, pp59-c-Fyn, PP2A and PI-3 kinase, and capable of activating the mitogen-activated protein kinase pathway (Dilworth, 1995) . Conceivably, MT could act as a downstream inhibitor of the p53 pathway.
The question of whether polyomavirus interferes with the p53 pathway is relevant for the assessment of the p53 status of polyomavirus-induced tumours. If polyomavirus does not block p53 function and if inactivation of p53 function is important or even essential for the development of polyomavirus-induced tumours, p53 mutations and\or deletions would be expected to occur at high frequency in polyomavirus-induced tumours. We found that 6 out of 15 polyomavirus-induced sarcomas expressed low levels of wildtype p53 and retained p53-mediated transcriptional transactivation of at least the p53-responsive MDM2 gene following MMC treatment (Tables 1 and 2 ). Four tumours in this group retained p53-mediated transactivation of WAF1\ p21 as well. The low induction of WAF1\p21 in SESO and SE7E indicates that the transcriptional transactivation function of p53 is partially deficient in these two tumours. It is noteworthy that SESO overexpressed MDM2, which may interfere with p53 function by binding the N-terminal transactivation domain of p53 (Oliner et al., 1993) . MDM2 levels were lower in SE7E, but still higher than the MDM2 levels in the other tumours that expressed low levels of wildtype p53 (Table 1) . SEYF, which expressed elevated levels of wild-type p53, also overexpressed the p53 antagonist MDM2. WAF1\p21 and MDM2 were only weakly induced following DNA damage in this tumour.
Eight out of the 15 tumours (53 %) carried mutant p53 or were p53-negative (Table 1) , and in general showed no significant induction of WAF1\p21 and MDM2 following MMC treatment. Although WAF1\p21 mRNA levels increased following MMC treatment in SEAC, the levels were much lower than those observed in the tumours that expressed wild-type p53. The moderate induction of MDM2 and WAF1\p21 in several of the tumours lacking wild-type p53 is consistent with work demonstrating that both genes are also regulated by p53-independent mechanisms (Barak et al., 1994 ; Michieli et al., 1994 ; Parker et al., 1995) .
Nevertheless, the fact that all tumours that carried mutant p53 were deficient in p53-mediated transcriptional transactivation supports the notion that the p53 point mutations identified indeed inactivate p53 function. Altogether 8 out of the 15 tumours examined (53 %) were p53-negative or carried p53 mutation, and another 3 tumours were deficient in transcriptional transactivation of one or two p53-responsive genes in response to p53 accumulation. This frequency of p53 mutation and\or inactivation is similar to that found in many non-virus-induced human and rodent tumours (Greenblatt et al., 1994) , indicating that inactivation of p53 is important for the development of polyomavirus-induced sarcomas, and that polyomavirus is unlikely to block p53 function in a manner sufficient to reduce the selective pressure for p53 point mutation or deletion during polyomavirus-induced tumorigenesis. It cannot be excluded, however, that polyomavirus interferes with the apoptosis-inducing effect of p53 in the context of lytic infection, a possibility not addressed here.
The majority of sarcomas in our study have been passaged serially in vivo. p53 mutations may have occurred during that passage. However, the two primary tumours examined, SEAC and SEWE, both carried mutant p53, indicating a selection for p53 mutation prior to in vivo passage.
Inactivation of p53 function may occur at different stages during multistep tumorigenesis or tumour progression in different tumours. Among the in vivo passaged tumours, two, SEWA and SEYF, are ascites sarcomas. SEWA carries mutant p53 whereas SEYF expresses high levels of MDM2 which can block p53 function. Previous work indicated that anaerobic adaptation is a characteristic of ascites tumours but not of tumours in general (Warburg & Hiepler, 1952) . Graeber et al. (1996) have recently reported that hypoxia induces apoptosis in tumour cells and that further genetic alterations, such as loss of p53 function or overexpression of Bcl-2, substantially reduce hypoxia-induced cell death. Our data are thus consistent with the possibility that p53 inactivation is an important requirement for the growth of originally polyomavirusinduced ascites sarcomas.
Polyomavirus LT, both full-length and truncated forms, was expressed in a subset of the sarcomas studied here, including sarcomas carrying only wild-type p53, sarcomas carrying mutant p53 and p53-negative sarcomas. In contrast, MT was expressed in all tumours examined, albeit at variable levels. Thus, neither LT nor MT expression correlated with p53 status. This further supports the idea that neither LT nor MT inactivate p53 in the course of polyomavirus-induced tumour development, although at least MT is required for expression and maintenance of the neoplastic phenotype.
